Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine ophthalmic nanoemulsion 0.05% vs emulsion 0.1% in dry eye disease
KCT0004516Phase 4Not yet recruiting
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of cyclosporine in dry eye syndrome (DED), sponsored by Taejoon Pharmaceutical Co., Ltd.. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on KCT0004516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004516.